{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:43:34Z","timestamp":1785908614188,"version":"3.56.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is a rare and potentially life-threatening bradykinin-mediated disorder most commonly associated with pathogenic variants in\n                      <jats:italic>SERPING1<\/jats:italic>\n                      . Data from Chinese patients remain limited, particularly regarding diagnostic delay,\n                      <jats:italic>SERPING1<\/jats:italic>\n                      allelic heterogeneity, and real-world use of lanadelumab prophylaxis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center retrospective observational study, we reviewed 10 consecutive unrelated index patients with confirmed HAE-C1INH managed at Henan Provincial People\u2019s Hospital from January 2022 to May 2026. Clinical data, complement results, and\n                      <jats:italic>SERPING1<\/jats:italic>\n                      Sanger sequencing findings were analyzed. Variants were classified according to ACMG\/AMP criteria. Seven patients received lanadelumab long-term prophylaxis. Annualized attack rates and Angioedema Control Test scores before and during prophylaxis were compared using the Wilcoxon signed-rank test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included 6 females and 4 males, with a mean age of 32.8\u2009\u00b1\u20099.9 years. Nine patients had HAE-C1INH type 1 and one had type 2. The mean age at symptom onset was 21.7\u2009\u00b1\u200911.1 years, and the mean diagnostic delay was 9.4\u2009\u00b1\u20097.0 years. All patients had recurrent peripheral edema, 7 had abdominal attacks, and 6 had facial and\/or laryngeal involvement. One patient required emergency tracheotomy. Serum C4 was reduced during attacks in all patients, and C1q levels were normal. Ten distinct heterozygous\n                      <jats:italic>SERPING1<\/jats:italic>\n                      variants were identified, including 3 frameshift variants, 6 missense variants, and 1 in-frame deletion. Among the 7 patients receiving lanadelumab, the median annualized attack rate decreased from 11 (IQR, 7\u201323) to 0 (IQR, 0\u20131) attacks\/year, and the median AECT score increased from 3 (IQR, 2\u20134) to 13 (IQR, 13\u201313). No serious adverse events were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective study showed substantial diagnostic delay, marked\n                      <jats:italic>SERPING1<\/jats:italic>\n                      allelic heterogeneity, and favorable real-world outcomes with lanadelumab prophylaxis in Chinese patients with HAE-C1INH. Earlier complement testing and access to appropriate genetic testing may shorten diagnostic delay. Larger prospective studies are needed to define individualized long-term prophylaxis strategies in Chinese patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/falgy.2026.1899305","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:43:29Z","timestamp":1785905009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic delay, SERPING1 allelic heterogeneity, and real-world lanadelumab prophylaxis in Chinese patients with hereditary angioedema due to C1 inhibitor deficiency"],"prefix":"10.3389","volume":"7","author":[{"given":"Wenjin","family":"Du","sequence":"first","affiliation":[{"name":"Department of Allergy, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Allergy, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Genetic Diseases and Functional Genomics, Medical Genetics Institute, Zhengzhou University People\u2019s Hospital, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Allergy, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Allergy, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Allergy, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Allergy, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University, People\u2019s Hospital of Henan University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-2133.2009.09366.x","article-title":"Hereditary angio-oedema in Denmark: a nationwide survey","volume":"161","author":"Bygum","year":"2009","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13023-015-0233-x","article-title":"A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy","volume":"10","author":"Zanichelli","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","article-title":"Epidemiology of bradykinin-mediated angioedema: a systematic investigation of epidemiological studies","volume":"13","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1684\/ejd.2013.2105","article-title":"Clinical features of hereditary angioedema in Chinese patients: new findings and differences from other populations","volume":"23","author":"Xu","year":"2013","journal-title":"Eur J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jaip.2022.12.021","article-title":"Epidemiology, management, and treatment access of hereditary angioedema in the Asia Pacific region: outcomes from an international survey","volume":"11","author":"Li","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/jcm10092023","article-title":"The genetics of hereditary angioedema: a review","volume":"10","author":"Santacroce","year":"2021","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/humu.23917","article-title":"SERPING1 Mutation update: mutation spectrum and C1 inhibitor phenotypes","volume":"41","author":"Ponard","year":"2020","journal-title":"Hum Mutat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100223","DOI":"10.1016\/j.jacig.2024.100223","article-title":"Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency","volume":"3","author":"Vincent","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.jaci.2021.01.011","article-title":"Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation","volume":"148","author":"Bork","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101335","DOI":"10.1016\/j.waojou.2026.101335","article-title":"The 2025 WAO guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities","volume":"19","author":"V\u00e1zquez","year":"2026","journal-title":"World Allergy Organ J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s12016-021-08836-7","article-title":"Leveraging genetics for hereditary angioedema: a road map to precision medicine","volume":"60","author":"Germenis","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41065-022-00242-z","article-title":"Mutation update of SERPING1 related to hereditary angioedema in the Chinese population","volume":"159","author":"Wang","year":"2022","journal-title":"Hereditas"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1007\/s10875-023-01565-w","article-title":"Systematic approach revealed SERPING1 splicing-affecting variants to be highly represented in the Czech national HAE cohort","volume":"43","author":"Grombirikova","year":"2023","journal-title":"J Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.alit.2019.12.009","article-title":"A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency","volume":"69","author":"Vatsiou","year":"2020","journal-title":"Allergol Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1565283","DOI":"10.3389\/falgy.2025.1565283","article-title":"Identification of an elusive SERPING1 deletion in a family with hereditary angioedema type I utilizing soft clipping","volume":"6","author":"Wetherby","year":"2025","journal-title":"Front Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.gene.2018.10.084","article-title":"Gene mapping strategy for alu elements rearrangements: detection of new large deletions in the SERPING1 gene causing hereditary angioedema in Brazilian families","volume":"685","author":"Nicolicht","year":"2019","journal-title":"Gene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12016-021-08897-8","article-title":"The mortality from hereditary angioedema worldwide: a review of the real-world data literature","volume":"62","author":"Minafra","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000545808","article-title":"Expert consensus on the diagnosis and treatment of hereditary angioedema in China (2024 edition)","volume":"187","author":"Xu","year":"2026","journal-title":"Int Arch Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/1346-8138.17106","article-title":"Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: report of five cases","volume":"51","author":"Hioki","year":"2024","journal-title":"J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5582\/irdr.2025.01045","article-title":"Three-year real-world outcomes of lanadelumab prophylaxis in hereditary angioedema: complete disease suppression and psychosocial benefits in two east Asian patients","volume":"14","author":"Takamura","year":"2025","journal-title":"Intractable Rare Dis Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000541242","article-title":"Initial experience of long-term prophylaxis with lanadelumab for hereditary angioedema in China: a clinical observation study on six patients","volume":"186","author":"Yao","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaip.2024.12.008","article-title":"Real-World effectiveness of lanadelumab in hereditary angioedema: multicountry INTEGRATED observational study","volume":"13","author":"Magerl","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/1346-8138.16909","article-title":"Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: a phase 3 multicenter, open-label study","volume":"50","author":"Hide","year":"2023","journal-title":"J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1673-8705.2019.01.001","article-title":"Expert consensus on the diagnosisand treatment of hereditary angioedema","volume":"13","author":"Zhi","year":"2019","journal-title":"Chin J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1710-1492-9-29","article-title":"Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe","volume":"9","author":"Zanichelli","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.anai.2013.07.012","article-title":"Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients","volume":"111","author":"Bouillet","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-9-44","article-title":"The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency","volume":"9","author":"Zotter","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1365-2249.2007.03438.x","article-title":"An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema","volume":"149","author":"Tarzi","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.clinbiochem.2017.04.007","article-title":"Complement factor C4 activation in patients with hereditary angioedema","volume":"50","author":"Aabom","year":"2017","journal-title":"Clin Biochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.jaip.2023.09.003","article-title":"Acquired angioedema due to C1-inhibitor deficiency (AAE-C1-INH)-A bicenter retrospective study on diagnosis, course, and therapy","volume":"11","author":"Trainotti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B40","doi-asserted-by":"publisher","first-page":"835503","DOI":"10.3389\/falgy.2022.835503","article-title":"SERPING1 Variants and C1-INH biological function: a close relationship with C1-INH-HAE","volume":"3","author":"Drouet","year":"2022","journal-title":"Front Allergy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1554940","DOI":"10.3389\/falgy.2025.1554940","article-title":"Case report: identification of a novel mutation, c.1067T\u2009>\u2009A, in the SERPING1 gene in a Chinese male with type 1 hereditary angioedema","volume":"6","author":"Du","year":"2025","journal-title":"Front Allergy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13223-021-00563-0","article-title":"Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study","volume":"17","author":"Hews-Girard","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"12184","DOI":"10.3390\/ijms241512184","article-title":"Neurologic and psychiatric manifestations of bradykinin-mediated angioedema: old and new challenges","volume":"24","author":"Mormile","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1696666","DOI":"10.3389\/falgy.2025.1696666","article-title":"Implementation of genetic diagnosis and personalized management of hereditary angioedema in a Chinese regional center: a community case study of three families","volume":"6","author":"Du","year":"2025","journal-title":"Front Allergy"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1899305\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:43:38Z","timestamp":1785905018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1899305\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":45,"alternative-id":["10.3389\/falgy.2026.1899305"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1899305","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1899305"}}